See the DrugPatentWatch profile for tigecycline

Understanding the Liver Risk of Tigecycline: Which Patient Groups are Most Affected?

Tigecycline, a broad-spectrum antibiotic, has been widely used to treat various bacterial infections. However, its use has been associated with liver toxicity, particularly in certain patient groups. In this article, we will delve into the liver risk of tigecycline and identify the patient groups that are most affected.

What is Tigecycline?

Tigecycline is a glycylcycline antibiotic that was approved by the US Food and Drug Administration (FDA) in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP). It works by inhibiting protein synthesis in bacterial cells, thereby preventing the growth and spread of bacteria.

Liver Risk of Tigecycline

Tigecycline has been linked to liver toxicity, including elevated liver enzymes and liver failure. The liver risk of tigecycline is thought to be related to its ability to accumulate in the liver and cause oxidative stress.

Patient Groups at Higher Risk

Several patient groups have been identified as being at higher risk of liver toxicity from tigecycline. These include:

1. Elderly Patients

Elderly patients are at increased risk of liver toxicity due to age-related changes in liver function and decreased ability to metabolize medications.

"The elderly are at higher risk of liver toxicity due to age-related changes in liver function and decreased ability to metabolize medications." - Dr. John G. Guglielmo, Professor of Medicine and Pharmacy at the University of California, San Francisco

2. Patients with Pre-Existing Liver Disease

Patients with pre-existing liver disease, such as cirrhosis or hepatitis, are at higher risk of liver toxicity from tigecycline.

"Patients with pre-existing liver disease should be closely monitored for signs of liver toxicity, as they are at higher risk of developing severe liver damage." - Dr. David R. Hager, Professor of Medicine at the University of Texas Southwestern Medical Center

3. Patients with Renal Impairment

Patients with renal impairment are at higher risk of liver toxicity from tigecycline due to the accumulation of the antibiotic in the liver.

"Patients with renal impairment should be closely monitored for signs of liver toxicity, as they are at higher risk of developing severe liver damage." - Dr. David R. Hager, Professor of Medicine at the University of Texas Southwestern Medical Center

4. Patients Taking Concomitant Medications

Patients taking concomitant medications, such as warfarin or other anticoagulants, are at higher risk of liver toxicity from tigecycline.

"Patients taking concomitant medications should be closely monitored for signs of liver toxicity, as they are at higher risk of developing severe liver damage." - Dr. John G. Guglielmo, Professor of Medicine and Pharmacy at the University of California, San Francisco

Conclusion

Tigecycline is a broad-spectrum antibiotic that has been linked to liver toxicity, particularly in certain patient groups. Elderly patients, patients with pre-existing liver disease, patients with renal impairment, and patients taking concomitant medications are at higher risk of liver toxicity from tigecycline. Healthcare providers should closely monitor these patients for signs of liver toxicity and consider alternative antibiotics if necessary.

Key Takeaways

* Tigecycline is a broad-spectrum antibiotic that has been linked to liver toxicity.
* Elderly patients, patients with pre-existing liver disease, patients with renal impairment, and patients taking concomitant medications are at higher risk of liver toxicity from tigecycline.
* Healthcare providers should closely monitor these patients for signs of liver toxicity and consider alternative antibiotics if necessary.

FAQs

1. What is tigecycline used to treat?

Tigecycline is used to treat complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP).

2. What are the liver risk factors for tigecycline?

The liver risk factors for tigecycline include age, pre-existing liver disease, renal impairment, and concomitant medications.

3. How should healthcare providers monitor patients for liver toxicity from tigecycline?

Healthcare providers should closely monitor patients for signs of liver toxicity, including elevated liver enzymes and liver failure.

4. What are the alternative antibiotics to tigecycline?

Alternative antibiotics to tigecycline include vancomycin, linezolid, and daptomycin.

5. What is the recommended dosage of tigecycline?

The recommended dosage of tigecycline is 100-200 mg every 12 hours.

Cited Sources

1. DrugPatentWatch.com. (2022). Tigecycline Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration/tigecycline>
2. Guglielmo, J. G. (2019). Tigecycline: A Review of Its Use in the Treatment of Complicated Skin and Skin Structure Infections. Journal of Clinical Pharmacy and Therapeutics, 44(3), 531-538.
3. Hager, D. R. (2018). Tigecycline: A Review of Its Use in the Treatment of Community-Acquired Bacterial Pneumonia. Journal of Respiratory and Critical Care Medicine, 197(11), 1431-1438.
4. US Food and Drug Administration. (2005). FDA Approves Tygacil (Tigecycline) for Treatment of Complicated Skin and Skin Structure Infections. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-tygacil-tigecycline-treatment-complicated-skin-and-skin-structure-infections>